Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

P3 Health Partners (PIII) Other Non-Current Liabilities (2021 - 2025)

P3 Health Partners (PIII) has disclosed Other Non-Current Liabilities for 5 consecutive years, with $5.0 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Other Non-Current Liabilities rose 1.65% year-over-year to $5.0 million, compared with a TTM value of $5.0 million through Jun 2025, up 1.65%, and an annual FY2024 reading of $10.3 million, changed N/A over the prior year.
  • Other Non-Current Liabilities was $5.0 million for Q2 2025 at P3 Health Partners, down from $10.3 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $15.7 million in Q2 2021 and bottomed at $869000.0 in Q1 2024.
  • Average Other Non-Current Liabilities over 5 years is $5.6 million, with a median of $4.9 million recorded in 2022.
  • Peak annual rise in Other Non-Current Liabilities hit 88.8% in 2024, while the deepest fall reached 82.29% in 2024.
  • Year by year, Other Non-Current Liabilities stood at $10.2 million in 2021, then plummeted by 53.07% to $4.8 million in 2022, then plummeted by 61.54% to $1.8 million in 2023, then surged by 459.22% to $10.3 million in 2024, then plummeted by 51.63% to $5.0 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for PIII at $5.0 million in Q2 2025, $10.3 million in Q4 2024, and $4.9 million in Q2 2024.